SCINAI IMMUNOTHERAPEUTICS LT (SCNI)
US09073Q3039 - ADR
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and...
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of...
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is spotlighted in this week’s episode of The BioMedWire Podcast. During the episode, Scinai Immunotherapeutics CEO Amir Reichman talks with host Carmel Fisher about SCNI’s […]
Scinai Regains Full Compliance with Nasdaq Listing Requirements
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; "Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, an affiliate of the largest shareholder of the company, Mr. Daniel Stone. Under the terms […]
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Scinai Immunotherapeutics (NASDAQ:SCNI) just reported results for the second qu...
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024
Scinai Immunotherapeutics just reported results for the second quarter of 2024.
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biopharmaceutical company focused on developing inflammation and immunology...
7 F-Rated Stocks for Your August 2024 Sell List
There's nothing wrong with taking a chance on an up-and-coming company, but these F-rated stocks to sell aren't worth your time.
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the Paul Erlich Institute (the PEI) for its drug development program towards Phase 1/2a...
PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition
Plug Power stock is up on Monday after the company announced EU approval for its acquisition of HyVia alongside Renault.
M Stock Plunges 13% as Macy’s Calls Off Take-Private Talks
Macy's stock is falling on Monday after M shareholders learned of it calling off plans for a deal that would take it private.
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
Scinai Immunotherapeutics stock is taking off on Monday with heavy trading of SCNI shares alongside new positive study results.
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I)...
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I)...
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I)...
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q1 2024
Scinai Immunotherapeutics just reported results for the first quarter of 2024.
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Scinai Immunotherapeutics (NASDAQ:SCNI) just reported results for the first qua...
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!